Therapeutics To Collaborate On Developing Suppliers & Manufacturers

Akshaya Bio Inc. (Akshaya) is a privately held development stage biotechnology company located in Edmonton, Alberta, Canada. Akshaya develops innovative therapeutics for infectious diseases and cancer. Akshaya's proprietary Chimigen® Platform ...

At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...

We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we seek to capitalize on ...

Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...

Cell Guidance Systems' mission is to develop products and services that enhance the human condition and protect our shared environment. We develop technologies that enable the delivery of bioactive molecules, controlling cell fate for medical, ...

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity ...

MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...

ViciniVax is a Dutch clinical stage biopharmaceutical company. It is a spin-off from the University Medical Center Groningen, the Netherlands, developing therapeutic cancer vaccines. Our first product candidate Vvax001, a therapeutic cancer vaccine ...

Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this ...

Dyve Biosciences created a breakthrough transdermal delivery platform that overturns the traditional limitations of administering therapies and allows for drug development across therapeutic areas. Our proprietary platform science can be applied to ...

APR Applied Pharma Research s.a. (APR) is a Swiss Pharma company dedicated to providing patients suffering from rare diseases with innovative treatments that make a real difference in their life. Our focus as a Swiss global health care company is ...

ImmunoDX, LLC (IDX) - formerly known as ImmunoDiagnostics - develops, manufactures and markets a wide range of specialty biologicals for Human T-cell Research/ Diagnostics, AIDS, HCV, HBV, TB, Cancer and Arthritis diagnostics and therapeutics ...

We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...

InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...

Based on our research, we believe that the common denominator underlying each intestinal microbiome is a network of interconnected, interdependent and metabolic functions that are essential for the host and the microbiome. PharmaBiome has developed ...

POP Biotechnologies, Inc. (POP BIO) is dedicated to addressing critical medical challenges with advanced nanotechnologies. POP BIO’s key breakthrough, the porphyrin-phospholipid (PoP) platform, facilitates the creation of powerful light-targeted ...

MODAG aims to provide a novel approach for treating neurodegenerative diseases by combining targeted small molecule therapeutics with the right diagnostic tools. Our first objective is to demonstrate clinical proof-of-concept with our lead compound ...

We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase ...

Third Pole Therapeutics develops and delivers critical life-sustaining cardio-pulmonary therapies. Warren Zapol, M.D., Third Pole’s founder, invented the first use for inhaled nitric oxide (iNO) for the treatment of hypoxic respiratory failure in ...

Superfluid’s platform technology is applicable to a wide variety of diseases. We are currently focused on Alzheimer’s Disease, where there are urgent medical needs. This minimally invasive approach eliminates the need for spinal taps and ...